Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good luck Longs.
Just realized my profits and will enjoy the evening
KS
NP, love when we all making money of people who steal shares:) Someone on ETRM board actually alerted it, it looked good but was missing volume so figured I would help out and give it a kick start!
We need some sellers, no shares available.
Thanks for the tip UT looking great!!
That's how we do it!! Gonna make ETRM look like pocket change:)
The next etrm!! With a smaller float and merger news!
Merger in the works!! Gonna be explosive with such a tiny float!!
Got ya let's see where this jewel goes today SGNL!!!
This is just getting started! Too early to scalp, tiny float and people just getting wind of this. Watch how shorties scramble to cover on a non existent float!
Trying to scalp a few here from $10.10 and GLTU!!!
Awesome there she goes!!! Thanks UT!!!
Back up, just the volatility halt getting triggered with the rapid moves!! 10s!!
Very Low floater, gonna be insane with volume!!
Is she halted?
Holy K-rap!!
Wow she moves fast SGNL!!!
Doesn't take much to move this, looking good!
Made some $k (12) as well. But the power party did not started yet....we need to be patient...6 weeks from now the latest.
Yeah, I bought 10k shares when it tanked to $3 and sold all at $13 when it spiked. How bout you.
Hey so did you guys make a $h!t ton of money on that reverse merger?.
MiRagen presented PH1 clinical trials (very positive) at ASH this weekend
https://ash.confex.com/ash/2016/webprogram/Paper93903.html
More Merger Documents posted on last Friday after the bell....
More News to come over the next couple of days....exciting Christmas days.
Good luck.
KS
News December 1, 2016:
On November 29, 2016, Signal Genetics, Inc. (“Signal”) entered into an Intellectual Property Purchase Agreement (the “IP Purchase Agreement”) with Quest Diagnostics Investments LLC (“Quest”). The consummation and closing of this transaction is subject to, among other things, Signal stockholder approval.
Pursuant to the IP Purchase Agreement, Signal has agreed to sell all of its intellectual property assets relating to the MyPRS test (collectively, the “MyPRS Assets”). As part of the sale of MyPRS Assets, Signal will assign all of its rights, interests and obligations to certain agreements, including, that certain License Agreement effective as of April 1, 2010, made by and between the Board of Trustees of the University of Arkansas acting for and on behalf of the University of Arkansas for Medical Sciences, a public institution of higher education, and Myeloma Health LLC, a Delaware limited liability company, as amended (collectively, the “UAMS License Agreement”). Quest agrees to be bound by the terms, obligations and conditions as a licensee under the UAMS License Agreement pursuant to an assignment and assumption agreement. Signal will also provide to Quest certain information technology, software and firmware related or required for the use of the MyPRS test.
As consideration for the sale of the MyPRS Assets, Quest will pay Signal $825,000, plus an additional $100,000 if Quest exercises the option to require Signal to operate Signal’s lab beyond December 31, 2016 (but not later than January 14, 2017). The closing of this transaction is anticipated to occur as promptly as practicable after Signal obtains stockholder approval and Signal and Quest satisfy all other conditions to closing.
Under the IP Purchase Agreement, Signal is required to indemnify Quest for any breaches of Signal’s representations, warranties, covenants and agreements for their applicable survival period and with respect to any retained liabilities and therefore Signal will have continuing potential liability to Quest following the closing. Quest agrees to indemnify Signal under the IP Purchase Agreement for any breaches of Quest’s representations, warranties or covenants and any assumed liabilities. The IP Purchase Agreement limits Signal’s aggregate liability for indemnification with respect to the breach of certain representations and warranties to $825,000 and $206,250 of this amount for the breach of other representations and warranties and such indemnification is subject to a nuisance provision such that Signal’s indemnification obligations are not triggered unless the aggregate amount of a claim, demand or loss exceeds $41,250.
Until the closing of the sale of the MyPRS Assets, Signal is prohibited from directly or indirectly soliciting, initiating, encouraging, accepting or entertaining any inquiries, offers or proposals from any other person or entity relating to any asset sale or similar transaction involving the MyPRS Assets (with the exception of operating the MyPRS test in the ordinary course of its business).
Under the terms of the IP Purchase Agreement, there are several conditions to closing. Among such conditions, neither Signal nor Quest is obligated to close the sale of the MyPRS Assets if (i) there is a court order or injunction prohibiting the sale of the MyPRS Assets, or (ii) Signal has not obtained stockholder approval for either the sale of the MyPRS Assets or the previously announced Agreement and Plan of Merger and Reorganization dated October 31, 2016, by and among Signal, Signal Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Signal (“Merger Sub”), and Miragen Therapeutics, Inc., a Delaware corporation (the “Merger Agreement”) . Signal’s and Quest’s obligation to close are also contingent upon additional customary closing conditions including, without limitation, the performance of other agreements, covenants and conditions under the IP Purchase Agreement and the execution of certain documents by the parties and delivery of certain closing certificates specified in the IP Purchase Agreement. The closing of the proposed merger contemplated by the Merger Agreement is expected to occur simultaneously with the closing of this transaction.
The IP Purchase Agreement may be terminated due to a number of reasons, including: (i) by mutual written consent of Quest and Signal; (ii) if there has been a material breach, inaccuracy or failure to perform any of the representations, warranties, covenants or agreements of a party as set forth in the IP Purchase Agreement; (iii) the closing of the sale of the MyPRS Assets has not occurred on or before April 30, 2017 (unless agreed to otherwise); (iv) the Merger Agreement has been terminated; (v) any law makes such sale illegal or otherwise prohibited; (vi) a governmental authority issues an order preventing or enjoining the consummation of the transaction; or (vii) a proceeding or investigation seeks material damages in connection with the proposed merger or the sale of the MyPRS Assets.
The preceding summary does not purport to be complete and is qualified in its entirety by reference to the IP Purchase Agreement, a copy of which is included as Exhibit 2.1 to this Current Report on Form 8-K and which is incorporated herein by reference.
Additional Information about the Proposed Merger and Where to Find It
In connection with the previously disclosed proposed merger between Signal Genetics, Inc. and Miragen Therapeutics, Inc., Signal and Miragen intend to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a proxy statement / prospectus / information statement. Investors and security holders of Signal and Miragen are urged to read these materials when they become available because they will contain important information about Signal, Miragen and the proposed merger and this proposed sale of the MyPRS Assets. The proxy statement / prospectus / information statement and other relevant materials (when they become available), and any other documents filed by Signal with the SEC, may be obtained free of charge at the SEC web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Signal by directing a written request to: Signal Genetics, Inc., 5740 Fleet Street, Carlsbad, CA 92008, Attention: Investor Relations. Investors and security holders are urged to read the proxy statement / prospectus / information statement and the other relevant materials when they become available before making any voting or investment decision with respect to the sale of the MyPRS Assets and the proposed merger.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
News from Nov 29:
miRagen Therapeutics Expands Executive Leadership Team
---------------------
Paul Rubin, M.D. Joins as Executive Vice President of Research and Development
BOULDER, CO., November 29, 2016 – miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative microRNA (miRNA)-targeting therapies in disease areas of high unmet medical need, today announced the appointment of Paul Rubin, M.D. to the position of Executive Vice President of Research and Development. Dr. Rubin is a seasoned biopharmaceutical executive with expertise across a range of drug modalities and therapeutic areas. He has been responsible for clinical development programs, which led to regulatory approval of several products during his career with several pharmaceutical and biotechnology companies.
“Paul brings an impressive breadth and depth of experience in drug discovery and development to our team.” said William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen. “I’m excited to welcome him to the miRagen team and look forward to working together to advance our product candidate portfolio.”
“I welcome the opportunity to contribute to the advancement of miRagen’s platform of RNA-based therapeutics”, said Dr. Rubin. “I am particularly excited to join the team presently managing miRagen’s two lead candidates, MRG-106 for the treatment of certain cancers, and MRG-201 for the treatment of pathological fibrosis as they continue to advance these products in clinical trials.”
Prior to joining miRagen, Dr. Rubin held various roles at Xoma Corporation from June 2011 to November 2016, most recently serving as its Chief Medical Officer, and Senior Vice President of Research and Development. Prior to joining Xoma Corporation, Dr. Rubin was the Chief Medical Officer at Funxional Therapeutics Ltd. from February 2011 to June 2011, the Chief Executive Officer of Resolvyx Pharmaceuticals, Inc. from 2007 to 2009 and the President and Chief Executive Officer of Critical Therapeutics, Inc. from 2002 to 2007.
From 1996 to 2002, Dr. Rubin held various roles with Sepracor, Inc., where he served as Senior Vice President, Development, and later as Executive Vice President, Research & Development. While at Sepracor he led the development of Sepracor’s internally developed approved products including Xopenex ® , Lunesta ® , Xopenex HFA ® and Brovana ® .
From 1993 to 1996, Paul held senior level positions at Glaxo-Wellcome Pharmaceuticals, including Vice President of Worldwide Clinical Pharmacology and Early Clinical Development. From 1987 to 1993, Dr. Rubin held various roles with Abbott Laboratories, including as Vice President, Immunology and Endocrinology, where he successfully advanced zileuton, the first 5-lipoxygenase inhibitor, from discovery to approval for the treatment of asthma.
Dr. Rubin received a B.A. from Occidental College and an M.D. from Rush Medical College. He completed his training in internal medicine at the University of Wisconsin.
SCIENTIFIC MEETING AND EDUCATION DAY OF THE
SOCIETY FOR NEURO-ONCOLOGY
November 17 - 20, 2016 - Scottsdale Fairmont Princess Hotel
Probably ppl expecting great news from the meeting today
Worry not its called low float mania.
$15. What is happening??
9 pre-market nice call!
5.43 today for the close still up trending so I'll take it. I also show the RSI at 18 which is super oversold IMO. well see if we can continue Monday! Have a great weekend all.
That would be .40 pre-split. It ran up to .57 after news about a week ago which is around 7.50 after 15 to 1 RS.
Who knows where this could run up to, or not.
200 shares after hour at 5.50. Tomorrow this could start testing 6 bucks which I'm hopeful for.
Nailed it!
Would love to see this close at 5 bucks again today.
What a day for SGNL! Perfect chase up all day long.
I was added the whole time before the split so I have a good size position. I'm really hoping this movement continues tomorrow
He probably took a position. That is known to change people's tune imo
Thought you had it going to zero. What changed your tune?
The target price for Signal Genetics Inc has increased to $33.75 from $2.25 in the last week. (https://stockflare.com/stocks/SGNL.O )
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1137
|
Created
|
02/13/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |